Icotrokinra: A Promising Oral IL-23 Receptor Inhibitor for Moderate-to-Severe Plaque Psoriasis
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
F Okundia, M Shakhashiro
Skin therapy letter, 2026
pubmed.ncbi.nlm.nih.gov
Biologics have emerged in recent years as relatively safe and effective options for managing plaque psoriasis, however, a subset of patients remain reluctant to initiate biologic therapy. Icotrokinra is a novel, first-in-class oral peptide that targets the interleukin-23 receptor and has demonstrated a favorable safety and efficacy profile comparable to that of injectable biologics in individuals aged 12 years and older. This review summarizes the clinical trial data regarding the safety and efficacy of icotrokinra.
